ArticleWorld journal of urology2025
Radical prostatectomy outcomes in patients with PI-RADS 5 lesions and favorable prostate cancer.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMen with Grade Group (GG) 1-2 prostate cancer (PCa) are generally candidates for active surveillance, yet the presence of a PI-RADS 5 lesion on mpMRI often prompts definitive treatment. Data on pathological outcomes in this specific subgroup remain scarce. The aim of this study was to assess the prevalence of adverse and aggressive pathology after radical prostatectomy (RP) and to identify predictors of biochemical recurrence (BCR).
methodsA retrospective, single-center study was conducted including 72 men with biopsy-proven GG 1-2 PCa and a PI-RADS 5 lesion on prebiopsy mpMRI, confirmed by local review, who underwent RP between 2017 and 2024. The primary endpoint was adverse (i.e., GG 3 and/or pT3a) or aggressive (i.e., GG ≥ 4 and/or pT3b and/or pN1) features at final pathology. Secondary endpoint was BCR-free survival.
resultsAt final pathology, 64% of men (n = 46) showed favorable features, 15% (n = 11) adverse pathology, and 21% (n = 15) aggressive pathology. When stratifying GG2 tumors by pattern-4 burden, both GG2 < 20% (HR 5.75, 95% CI 1.25-26.33; p = 0.024) and GG2 ≥ 20% (HR 8.26, 95% CI 1.84-37.01; p = 0.006) were independently associated with adverse/aggressive pathology compared with GG1. After a median follow-up of 28 months, 13 men developed BCR (3-year BCR-free survival: 89%). In multivariable Cox analysis, only aggressive pathology at RP was independently associated with BCR (HR 5.42, 95% CI 1.3-24; p = 0.025).
conclusionsAmong men with PI-RADS 5/GG1-2 PCa, one third harbor adverse or aggressive features at RP. The burden of Gleason pattern 4 plays a key role in stratifying risk within GG2 disease. While AS may remain suitable for carefully selected GG1 patients with confirmatory reassurance, GG2 tumors, particularly those with substantial pattern-4 volume, demonstrate less favorable pathological profiles and warrant individualized counseling.
Indexed as
Identifiers
41454938What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.